Research Programme: nucleotide-competing reverse transcriptase inhibitors - Tibotec

Drug Profile

Research Programme: nucleotide-competing reverse transcriptase inhibitors - Tibotec

Alternative Names: NCRTI-1

Latest Information Update: 20 Feb 2008

Price : $50

At a glance

  • Originator McGill University; Tibotec BVBA
  • Class Pyridones; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 20 Feb 2008 This programme is still in active development
  • 22 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top